SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
 
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
LEA GREGORY S

(Last) (First) (Middle)
2800 PATTON ROAD

(Street)
ST. PAUL MN 55113

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
EnteroMedics Inc [ ETRM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CFO and CCO
3. Date of Earliest Transaction (Month/Day/Year)
02/25/2016
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 184(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $28.5(1) (2) 10/29/2017 Common Stock 1,114 1,114(1) D
Stock Option (right to buy) $28.5(1) (2) 10/29/2017 Common Stock 260 260(1) D
Stock Option (right to buy) $28.5(1) (2) 10/29/2017 Common Stock 1,074 1,074(1) D
Stock Option (right to buy) $28.5(1) (2) 10/29/2017 Common Stock 973 973(1) D
Stock Option (right to buy) $56.7(1) (2) 11/18/2019 Common Stock 1,111 1,111(1) D
Warrant (common stock right to buy) $32.85(1) (3) (4) Common Stock 666 666(1) D
Stock Option (right to buy) $38.7(1) (2) 02/16/2021 Common Stock 13,333 13,333(1) D
Stock Option (right to buy) $40.05(1) (2) 07/12/2021 Common Stock 15,000 15,000(1) D
Stock Option (right to buy) $28.5(1) (2) 12/14/2021 Common Stock 8,333 8,333(1) D
Stock Option (right to buy) $50.25(1) 08/10/2012(5) 07/10/2022 Common Stock 57,543 57,543(1) D
Stock Option (right to buy) $19.65(1) 06/30/2013(5) 05/31/2023 Common Stock 66,885 66,885(1) D
Stock Option (right to buy) $16.65(1) 04/09/2015(5) 03/09/2025 Common Stock 11,666 11,666(1) D
Stock Option (right to buy) $1.07 02/25/2016 A 50,000 02/25/2016 02/25/2026 Common Stock 50,000 $0.00 50,000 D
Explanation of Responses:
1. On January 6, 2016, EnteroMedics Inc. effected a 1-for-15 reverse stock split of its issued and outstanding shares of common stock, par value $0.01 per share, resulting in a proportional decrease in the total shares of common stock beneficially owned by the reporting person. all previously reported exercise prices, option grants and similar instruments convertible into common stock were proportionally adjusted to reflect the reverse split.
2. Options currently 100% vested.
3. Warrant becomes exercisable 181 days from the date of issuance at close of offering.
4. Warrant expires five years from date it first becomes exercisable.
5. Vests in increments of 1/48th per month, beginning the date shown.
Remarks:
THIS FILING REFLECTS THE POST SPLIT NUMBERS OF ALL SHARES, OPTIONS AND SIMILAR INSTRUMENTS HELD BY THE REPORTING PERSON AS PREVIOUSLY REPORTED.
/s/ Greg S. Lea 02/29/2016
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.